Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast cancer patient-derived xenograft models

Authors

Zhanfang Guo, Washington University School of Medicine in St. Louis
Tina Primeau, Washington University School of Medicine in St. Louis
Jingqin Luo, Washington University School of Medicine in St. Louis
Cynthia Zhang, Washington University School of Medicine in St. Louis
Hua Sun, Washington University School of Medicine in St. Louis
Jeremy Hoog, Washington University School of Medicine in St. Louis
Feng Gao, Washington University School of Medicine in St. Louis
Shixia Huang, Baylor College of Medicine
Dean P Edwards, Baylor College of Medicine
Sherri R Davies, Washington University School of Medicine in St. Louis
Rebecca Aft, Washington University School of Medicine in St. Louis
Li Ding, Washington University School of Medicine in St. Louis
Matthew J Ellis, Baylor College of Medicine
Shunqiang Li, Washington University School of Medicine in St. Louis
Cynthia X Ma, Washington University School of Medicine in St. Louis

Journal

Cancers (Basel)

Publication Date

2020

Volume

12

Issue

12

Document Type

Open Access Publication

DOI

10.3390/cancers12123857

Rights and Permissions

Guo Z, Primeau T, Luo J, et al. Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. Cancers (Basel). 2020;12(12):3857. Published 2020 Dec 21. doi:10.3390/cancers12123857

Recommended Citation

Guo, Zhanfang; Primeau, Tina; Luo, Jingqin; Zhang, Cynthia; Sun, Hua; Hoog, Jeremy; Gao, Feng; Huang, Shixia; Edwards, Dean P; Davies, Sherri R; Aft, Rebecca; Ding, Li; Ellis, Matthew J; Li, Shunqiang; and Ma, Cynthia X, "Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast cancer patient-derived xenograft models." Cancers (Basel). 12, 12. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9953